DUBLIN, Ireland and LONDON, July 6 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (“Alltracel”, or “the Company”), (AIM: AP.L), the Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets is pleased to confirm Q2 revenue of EUR5.1M up 17% versus last quarter (Q1 2006) and up 19% versus the same quarter last year (Q2 2005) resulting in total first half 2006 revenues of EUR9.5M up 13% versus the first half of 2005.
Highlights of the second quarter include:
- Year on year group revenue growth of 19% -- driven by strong re-order levels and contract wins, across Europe in both the Woundcare and Oralcare businesses
- Woundcare regulatory breakthroughs in Asia:
- Chinese regulatory approval for several m-doc(TM) based products secured by Alltracel’s woundcare partner Yunnan Baiyao enabling commencement of sales in China later this year; and
- Significant progress on m-doc(TM) regulatory discussions in Japan enabling commencement of shipments to Japanese partner Nichiban in Q3 2006.
- Completion of both sterol and statin pre-clinical trials confirming successful combination results of Alltracel’s bioactive for the cardiovascular health marketplace:
- The sterol combination trial confirmed that, on average, the sterol based product’s LDL ‘Bad’ cholesterol reducing ability was improved by 91% when combined with Alltracel’s bioactive; and
- The statin combination trial result confirmed that the combination of a commercially available statin with the Alltracel bioactive results in significant complementary cardiovascular health benefits.
- Continued strong growth in Oralcare
- Strong ongoing orders and new contract wins across Europe.
Alltracel’s Chief Executive Officer, Tony Richardson, commented:
“We are pleased with this quarter’s solid, 19% year-on-year revenue growth driven by strong re-order levels across the group businesses. We believe this level of growth will continue into the second half of the year following the clearing of the woundcare regulatory hurdles in China and Japan as well as expected new business wins in Oralcare
We also saw significant breakthroughs in our cardiovascular health business in terms of positive trials and developments of key partnerships. In addition, last month’s successful sterol combination trial result has accelerated our commercial opportunities as was evidenced during our participation at the Institute of Food Technologists Expo trade fair last week in Orlando where the combination trial results garnered significant interest from potential partners.”
Overall significant progress has been made in the fist six months and we are looking forward to an exciting second half. We remain committed to building sustainable profitable revenue through managing our cost base carefully while continuing to drive new partnerships and technology developments as well as utilising Alltracel’s core technology for new market sector entries.”
For Further Information Contact: Dublin: Karen Coleman Alltracel: +353-1-235-2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44(0)207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626 Notes to Editors follow:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London’s Alternative Investment Market in July 2001.
Alltracel’s has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel’s patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent.
- In the consumer Woundcare sector m-doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.
- Alltracel’s woundcare technology is also currently poised for entry into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following two years of scientific research including in vitro, pre-clinical and clinical trials indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
Alltracel’s patented process utilises a derivative of cellulose fibre to produce a bioactive with scientifically proven properties that aid CVH; specifically lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other bio-actives) studies to determine optimum delivery systems, formats and combinations in both the functional foods and pharmaceutical markets are underway.
- Development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Alltracel Pharmaceuticals Plc.
CONTACT: Dublin: Karen Coleman, Alltracel: +353-1-235-2162,press@alltracel.com, London: Deborah Scott, Financial Dynamics:+44(0)207-831-3113, New York: Sean Leous, Financial Dynamics:+1-212-850-5626
